{"id":"kn026","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL4594568","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"KN026 functions as a bispecific monoclonal antibody designed to engage both HER2 and HER3 on the surface of tumor cells, preventing ligand-induced activation and downstream proliferation signals. By targeting two complementary receptors in the HER family, it aims to overcome resistance mechanisms that can develop with single-target HER2 inhibitors. This dual-targeting approach is intended to provide enhanced anti-tumor activity in HER2-expressing malignancies.","oneSentence":"KN026 is a bispecific antibody that simultaneously binds to HER2 and HER3 receptors to block their signaling pathways in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:53.790Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HER2-positive gastric cancer"},{"name":"HER2-positive breast cancer"}]},"trialDetails":[{"nctId":"NCT07441460","phase":"PHASE3","title":"A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2026-03-07","conditions":"Resectable HER2-positive Breast Cancer","enrollment":1800},{"nctId":"NCT07332533","phase":"PHASE2, PHASE3","title":"A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2025-12-30","conditions":"HER2-positive Gastric Cancer","enrollment":490},{"nctId":"NCT06998771","phase":"PHASE2","title":"JSKN003 Combined Treatment of HER2-positive Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2025-06-15","conditions":"HER2-positive Gastric Cancer","enrollment":153},{"nctId":"NCT05838066","phase":"PHASE3","title":"Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.","status":"RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2023-07-23","conditions":"First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer","enrollment":880},{"nctId":"NCT06747338","phase":"PHASE3","title":"A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer","status":"RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2024-12-16","conditions":"Early or Locally Advanced HER2-positive Breast Cancer","enrollment":520},{"nctId":"NCT06023758","phase":"PHASE2","title":"Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC","status":"RECRUITING","sponsor":"Peking University","startDate":"2023-09-22","conditions":"HER2-positive Locally Advanced Resectable Gastric Cancer","enrollment":18},{"nctId":"NCT04040699","phase":"PHASE1","title":"KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor","status":"COMPLETED","sponsor":"Peking University","startDate":"2019-09-26","conditions":"HER2 Positive Solid Tumor","enrollment":48},{"nctId":"NCT03925974","phase":"PHASE2","title":"KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer","status":"COMPLETED","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2019-06-17","conditions":"Gastric/Gastroesophageal Junction Cancer","enrollment":45},{"nctId":"NCT03619681","phase":"PHASE1","title":"Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer","status":"COMPLETED","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2018-09-17","conditions":"Breast Cancer, Gastric Cancer","enrollment":63},{"nctId":"NCT05427383","phase":"PHASE2, PHASE3","title":"KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy","status":"RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2022-04-07","conditions":"Stomach Cancer","enrollment":286},{"nctId":"NCT04521179","phase":"PHASE2","title":"Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors","status":"COMPLETED","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2020-12-07","conditions":"HER2-positive Solid Tumors","enrollment":102},{"nctId":"NCT04165993","phase":"PHASE2","title":"Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2019-12-31","conditions":"Metastatic Breast Cancer","enrollment":68},{"nctId":"NCT05985707","phase":"PHASE2","title":"KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2023-08-15","conditions":"HER2-positive Colorectal Cancer, HER2-positive Biliary Tract Cancer","enrollment":80},{"nctId":"NCT04778982","phase":"","title":"Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer","status":"TERMINATED","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2022-05-25","conditions":"HER2-positive Metastatic Breast Cancer","enrollment":4},{"nctId":"NCT04881929","phase":"PHASE2","title":"Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer","status":"UNKNOWN","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2021-08-09","conditions":"Breast Cancer","enrollment":30},{"nctId":"NCT03847168","phase":"PHASE1","title":"KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer","status":"UNKNOWN","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2019-06-18","conditions":"Breast Cancer, Gastric/Gastroesophageal Junction Cancer","enrollment":22}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Docetaxel","KN046","IO therapy"],"phase":"phase_3","status":"active","brandName":"KN026","genericName":"KN026","companyName":"Shanghai JMT-Bio Inc.","companyId":"shanghai-jmt-bio-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"KN026 is a bispecific antibody that simultaneously binds to HER2 and HER3 receptors to block their signaling pathways in cancer cells. Used for HER2-positive gastric cancer, HER2-positive breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}